- Home
- WRBY vs SUPN Comparison
WRBY vs SUPN Comparison
Compare WRBY & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRBY
- SUPN
- Stock Information
- Founded
- WRBY 2010
- SUPN 2005
- Country
- WRBY United States
- SUPN United States
- Employees
- WRBY N/A
- SUPN N/A
- Industry
- WRBY Ophthalmic Goods
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- WRBY Health Care
- SUPN Health Care
- Exchange
- WRBY Nasdaq
- SUPN Nasdaq
- Market Cap
- WRBY 2.1B
- SUPN 1.8B
- IPO Year
- WRBY 2021
- SUPN 2012
- Fundamental
- Price
- WRBY $21.18
- SUPN $31.70
- Analyst Decision
- WRBY Buy
- SUPN Hold
- Analyst Count
- WRBY 15
- SUPN 2
- Target Price
- WRBY $23.33
- SUPN $36.00
- AVG Volume (30 Days)
- WRBY 3.6M
- SUPN 467.8K
- Earning Date
- WRBY 05-08-2025
- SUPN 05-06-2025
- Dividend Yield
- WRBY N/A
- SUPN N/A
- EPS Growth
- WRBY N/A
- SUPN N/A
- EPS
- WRBY N/A
- SUPN 1.11
- Revenue
- WRBY $795,094,000.00
- SUPN $667,997,000.00
- Revenue This Year
- WRBY $15.94
- SUPN N/A
- Revenue Next Year
- WRBY $13.73
- SUPN $8.74
- P/E Ratio
- WRBY N/A
- SUPN $28.64
- Revenue Growth
- WRBY 13.94
- SUPN 11.82
- 52 Week Low
- WRBY $12.46
- SUPN $25.53
- 52 Week High
- WRBY $28.68
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- WRBY 66.39
- SUPN 45.77
- Support Level
- WRBY $19.38
- SUPN $31.56
- Resistance Level
- WRBY $20.90
- SUPN $32.85
- Average True Range (ATR)
- WRBY 1.13
- SUPN 0.78
- MACD
- WRBY 0.32
- SUPN -0.08
- Stochastic Oscillator
- WRBY 80.81
- SUPN 13.56
About WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.